Latest Updates

On June 7, the Federal Trade Commission (FTC) announced that it will begin an inquiry into PBM practices – particularly the actions of the 6 largest PBMs (CVS Caremark, Express Scripts (ESI), Optum, Humana, Prime, & MedImpact).

Jenni Zilka, SVP, Community & Specialty Pharmacy and President, Good Neighbor Pharmacy and Kevin Ban, Chief Medical Officer, Walgreens, have co-authored an article that urges the passage of H.R. 7213, the Equitable Community Access to Pharmacist Services Act, bipartisan federal legislation that enables patients to continue to receive treatment from pharmacists for pandemic-related and respiratory health conditions.

AmerisourceBergen is a member of the Alliance to Modernize Prescribing Information (AMPI) – a group of pharmaceutical stakeholders with a common interest in advancing regulatory or legislative reforms to facilitate the dissemination of FDA-approved pharmaceutical labeling information via modern digital platforms. For more information on the issue, please visit AMPI’s website.

On May 24th, U.S. Senators Maria Cantwell (D-WA), Chair of the Senate Committee on Commerce, Science, and Transportation, and Chuck Grassley (R-IA), Ranking Member of the Senate Judiciary Committee, introduced the Pharmacy Benefit Manager Transparency Act of 2022, which would empower the Federal Trade Commission (FTC) to increase drug pricing transparency and hold PBMs in both commercial and government sponsored/funded plans accountable for “unfair and deceptive practices that drive up the costs of prescription drugs at the expense of consumers.”

On May 5, the U.S. Senate Commerce, Science and Transportation Committee’s Subcommittee on Consumer Protection, Product Safety, and Data Security held a hearing titled, “Ensuring Fairness and Transparency in the Market for Prescription Drugs,” which “examine[d] steps Congress can take to increase transparency in drug prices, require PBMs to operate fairly, and ensure the FTC has the authority it needs to stop unfair practices in the prescription drug market.”